| Genomic Medicine |
0 |
0.94 |
| Prostate Cancer |
0 |
0.94 |
| Renal Cell Carcinoma |
0 |
0.9 |
| Kidney Cancer |
0 |
0.76 |
| Cancer |
0 |
0.65 |
| Biologic Therapy |
0 |
0.63 |
| Bladder Cancer |
0 |
0.58 |
| Management of Localized Prostate Cancer |
0 |
0.58 |
| Metastasis |
0 |
0.52 |
| Nephrolithiasis |
0 |
0.43 |
| Clinical Guidelines |
0 |
1 |
| Kidney |
0 |
0.35 |
| End-Stage Renal Disease |
0 |
0.31 |
| Renal Disease |
0 |
0.31 |
| Prostate |
0 |
0.29 |
| Genetics |
0 |
0.18 |
| Laser |
0 |
0.18 |
| Social Determinants of Health |
0 |
0.13 |
| Bladder |
0 |
0.12 |
| Health Care Delivery |
0 |
0.12 |
| Radical Prostatectomy |
0 |
0.08 |
| Antigens |
0 |
0.06 |
| Biopsy |
0 |
0.06 |
| Contrast Medium |
0 |
0.06 |
| Cystectomy |
0 |
0.06 |
| Dorsum |
0 |
0.06 |
| Extracorporeal Shockwave Lithotripsy |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Immunotherapy |
0 |
0.06 |
| Mobility |
0 |
0.06 |
| Muscle |
0 |
0.06 |
| Neobladder |
0 |
0.06 |
| Pain |
0 |
0.06 |
| Pain Management |
0 |
0.06 |
| Partial Nephrectomy |
0 |
0.06 |
| Positron Emission Tomography |
0 |
0.06 |
| Prostatectomy |
0 |
0.06 |
| Radiation Therapy |
0 |
0.06 |
| Refractory |
0 |
0.06 |
| Ureteroscopy |
0 |
0.06 |